Investor Presentaiton
Evolution of Jubilant Pharma
FY18
US$619m
Revenue Contribution(¹)
Growth: 22.9%
FY19
US$761m
CDMO
30.3%
6.8%
16.3
7.0 %
%
14.0
%
42.8
%
19.9
%
Generics
19.9%
46.4%
Specialty
Pharmaceuticals
49.9%
CDMO
27.6%
14.7%
12.9%
19.2%
JLL acquired
API business -
Nanjangud,
Karnataka,
India
Acquired a majority stake in
Cadista Holdings Inc.
(generics pharmaceutical
company in the US) with a
USFDA approved
manufacturing facility for
solid dosage formulations
Acquired Draxis Pharma
Inc. in Canada
(manufacturer of sterile
products, non-sterile
products and
radiopharmaceuticals)
SGX-listed high
yield bond
offering
Completed
acquisition of
Triad's
radiopharmacies in
the US
FY03 FY04 FY05 FY06 FY07 FY08 FY09 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18
Generics
19.9% I
Specialty
Pharmaceuticals
53.2%
Acquired
Pharmaceutical
Services
Incorporated
Created R&D
centre for solid
dosage
formulations
N.V. and PSI
Supply N.V.
(Belgium)
Radiopharma
Allergy Therapy Products
CMO
Active Pharmaceutical Products
Solid Dosage Formulations
Acquired
HollisterStier
Laboratories
LLC in US (a
CMO service
provider)
Fund raising
from IFC
through a mix
of debt and
convertible
instruments
Acquired
balance of
minority stake
in Cadista
Holdings Inc.
Consolidation of
the
pharmaceutical
business under
JPL
Continued Focus on Specialty Pharmaceuticals - Radiopharma and Allergy Therapy Products
(1)
Revenue from operations include contribution from Radiopharmacies business from the period starting September 1, 2017
JUBILANT
PHARMAView entire presentation